H.R. 1750

119th Congress

In Committee

HEARD Act of 2025

Sponsored byDemocrat:Rep. Strickland, Marilyn [D-WA-10]WA· Introduced 27 février 2025

5

Cosponsors

5

Actions

0

Amendments

0

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

27 février 2025·1 year ago

Summary

Introduced in House · Updated 26 août 2025

Health Equity and Rare Disease Act of 2025 or the HEARD Act of 2025

This bill establishes Department of Health and Human Services (HHS) grants and other initiatives to address rare diseases or conditions (e.g., those affecting less than 200,000 people in the United States) in racial and ethnic minority populations. 

For example, to advance such purposes, the bill establishes within HHS

  • grants to public and private nonprofit entities for data collection and public outreach,
  • grants to health professions schools to improve health care and minority representation in research regarding rare diseases and conditions,
  • grants to tribal epidemiology centers and tribal and urban Indian health centers for research regarding rare diseases and conditions in tribal communities,
  • scholarships and educational loan repayment for medical school students who agree to work as health care professionals serving populations with rare diseases or conditions,
  • initiatives to coordinate research and other activities across the National Institutes of Health, and
  • public health awareness and education campaigns.

Also, the bill requires HHS to submit various reports to Congress on topics including (1) the federal government’s research and public health activities regarding rare diseases or conditions in minority populations, (2) regulatory barriers to treating rare diseases in Medicare beneficiaries of color, and (3) strategies for research and development of treatments for rare diseases or conditions that disproportionately impact minority populations.

Timeline

5 actions

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    27 février 2025 · IntroReferral

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    27 février 2025 · IntroReferral

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    27 février 2025 · IntroReferral

  4. Introduced in House

    27 février 2025 · IntroReferral

  5. Introduced in House

    27 février 2025 · IntroReferral

Sponsorship

5 cosponsors

Cosponsors

  • Democrat5100%

Classification

Policy area

Health

Cosponsor momentum

Cumulative over time

Cosponsors grew from 0 on 27 février 2025 to 5 on 2 septembre 2025.

Pelosi Tracker
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.